Gland Pharma Limited
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model…
What Gland files
- Others76
- Investor Meet74
- Important27
- Updates23
- Board Meeting11
- PPTs6
Gland Pharma partnered with a global pharma company for a full-service CDMO agreement to manufacture sterile injectable products. This collaboration covers 55 SKUs across three sites, with expected annual revenue potential of USD 90-100 million starting 2029, boosting long-term visibility.
Gland Pharma will hold its 48th Annual General Meeting on August 25. The company announced a final dividend of Rs. 20 per share for FY25-26, with the record date set for August 11 and payment by September 24.
Gland Pharma boosts sustainability: increased Capex for environmental tech, including solar projects & Zero Liquid Discharge. Achieved lower water and GHG emission intensities. Significantly increased local and MSME-sourced input materials. Maintained clear record with no safety incidents or regulatory fines.
Gland Pharma Limited has informed the Exchange regarding 'Allotment of Equity Shares on exercise of ESOPS'.
Gland Pharma's Independent Director resigned, citing a potential conflict of interest. A company where he is a Promoter intends to enter a business segment similar to Gland Pharma's planned future ventures.